阅读说明：本技术 脂联素分泌促进剂 (Adiponectin secretion promoter ) 是由 屋宏典 大野智 阪上未纪 藤山尚二郎 上山泰男 于 2019-07-17 设计创作，主要内容包括：本发明提供一种含有岛蓟、优选含有岛蓟叶的干燥粉末的脂联素分泌促进剂、含有该脂联素分泌促进剂的脂联素分泌促进用饮食品。(The invention provides an adiponectin secretion promoter containing artichoke, preferably dried powder containing artichoke leaves, and an adiponectin secretion promoting food or beverage containing the adiponectin secretion promoter.)

1. An adiponectin secretion promoter contains Cynara scolymus.

2. The adiponectin secretion promoter according to claim 1, which contains a dried powder of Cynara scolymus.

3. A food or beverage for promoting adiponectin secretion comprising the adiponectin secretion promoter according to claim 1 or 2.

Technical Field

The present invention relates to an adiponectin secretion promoter.

Background

Cirsium islandicum (Cirsium brevicaulum a. gray) is a plant belonging to the genus Cirsium of the family compositae. Japanese artichoke is widely grown on the coast of islands south of deer island. Island thistle is not only a traditional food material, but also is used as a crude drug in the Okinawa and the expanda. The present inventors reported that when artichoke powder was administered simultaneously to mice given a high-fat diet, the concentration of fatty acids in the blood was reduced, the amount of subcutaneous fat was reduced, the amount of liver fat was reduced, and the expression of fatty acid synthase was inhibited (patent document 1 and non-patent document 1).

Adiponectin is a cytokine (adipocytokine) secreted by adipocytes, and is known as a beneficial adipocytokine. Adiponectin is known to be closely related to lifestyle-related diseases such as circulatory diseases, diabetes, and obesity. When a high-fat diet is administered to type 2 diabetes model mice, adipocyte hypertrophy and deterioration of insulin resistance are induced, and the blood adiponectin concentration is significantly reduced. On the other hand, when adiponectin is supplemented to an obese type 2 diabetic model mouse that has been fed a high-fat diet, insulin resistance is improved (non-patent document 2). Adiponectin gene-deficient mice exhibit various symptoms of metabolic syndromes such as insulin resistance, impaired glucose tolerance, impaired lipid metabolism, and hypertension. Therefore, it is considered that the decrease in adiponectin level due to obesity is at least a part of the causes of impaired glucose tolerance, abnormal lipid metabolism, and hypertension.

Documents of the prior art

Patent document

Patent document 1: international publication WO2015/022978

Non-patent document

Non-patent document 1: inafuku M, et al. Cirsium brevicaule A. Gray leaf inhibition introduction in 3T3-L1 cells and C57BL/6 micron, Lipids Health Dis.2013Aug 15; 12:124.

Non-patent document 2: yamauchi T, et al, The fat-derived hormon adiponectin derivatives associated with a bone lipid activity and activity, Nature med 7:941-946,2001.

Disclosure of Invention

Technical problem to be solved by the invention

The technical problem of the present invention is to provide a novel adiponectin secretion promoter which is safe and low in toxicity and can be taken for a long period of time.

Means for solving the problems

In order to solve the above-described problems, the present invention includes the following inventions.

[1] An adiponectin secretion promoter contains Cynara scolymus.

[2] The adiponectin secretion promoter according to the above [1], which contains a dried powder of Cynara scolymus.

[3] A food or beverage for promoting adiponectin secretion comprising the adiponectin secretion promoter according to any one of the above [1] and [2 ].

Effects of the invention

The present invention provides an adiponectin secretion promoter which is effective for humans and can be administered for a long period of time with safety and low toxicity.

Detailed Description

In order to investigate the effect of artichoke on lipid metabolism in humans, the present inventors conducted clinical trials on 24 japanese adults and women with a critical LDL cholesterol level or marginally elevated level (120-159 mg/dL), or a moderately elevated level and marginally elevated neutral fat value (120-199 mg/dL). The dried powder of Cynara scolymus L was taken three times a day (3 g.times.3/day) for 12 weeks, and as a result, it was found that the blood adiponectin level significantly increased after 8 weeks and 12 weeks of the intake. Therefore, Cynara scolymus is known to be useful as an active ingredient of adiponectin secretion promoter.

The present invention provides an adiponectin secretion promoter containing artichoke. The Cynara scolymus L can be used for cultivating Cynara scolymus L for any number of days. The site to be used is not particularly limited, and may be any of leaves, stems, roots, rhizomes, fruits, seeds, seed coats, flowers, and the like of Cynara scolymus L. Leaves of Cynara scolymus are preferred.

In the adiponectin secretion promoter of the present invention, the Cynara scolymus can be used either directly as fresh Cynara scolymus or after drying. It can also be used in the form of dried powder, lyophilized powder, squeezed juice, or extract. The artichoke can be dried by a known drying method such as natural drying, hot air (warm air) drying, cold air drying, reduced pressure drying, or freeze drying. The powder preparation can be carried out, for example, by pulverizing dried artichoke using a commercially available pulverizer and then removing non-powder substances. The juicing may be performed using a commercially available juicer. The extract can be obtained by extracting Cynara scolymus with solvent. The island thistle for extraction can be fresh island thistle, minced fresh island thistle, or dried island thistle, or pulverized dried island thistle.

The solvent used for extraction can be water, alcohols, hexane, chloroform, ethers, esters, and ketones. Examples of the alcohols include ethanol, methanol, n-propanol, isopropanol, n-butanol, 1, 3-butanediol, propylene glycol, and glycerol. Examples of the ethers include diethyl ether and propyl ether. Examples of the esters include butyl acetate and ethyl acetate. Examples of the ketone include acetone and methyl ethyl ketone. A mixed solvent in which 2 or 3 or more of these solvents are combined may also be used. Further, for example, after the extraction with hexane, the obtained residue may be subjected to an extraction with chloroform, and thus different solvents may be used in combination in the extraction in order.

The Cynara scolymus extract can be in any state of extractive solution, concentrated or diluted extractive solution, coagulated extractive solution, or dried extractive solution.

The adiponectin secretion promoter of the present invention may contain a dry powder of artichoke, may contain a freeze-dried powder of artichoke, may contain a dry powder of artichoke leaves, and may also contain a freeze-dried powder of artichoke leaves. Such a dry powder or lyophilized powder can be prepared by a known method. The lyophilized powder of artichoke leaves can be prepared, for example, by the methods described in the examples.

The adiponectin secretion promoter of the present invention can significantly increase the concentration of adiponectin in blood, and it is known that adiponectin supplementation is effective for improving insulin resistance (non-patent document 2), reducing liver damage (Fukushima J, et al, Hepatol Res.2009Jul; 39(7): 724-.

The adiponectin secretion promoter of the present invention is useful for treating or improving hypoadiponectin. Here, hypoadiponectin anemia is a state expected to improve health conditions by promoting adiponectin secretion in vivo.

In addition, the adiponectin secretion promoter of the present invention is useful for treating or ameliorating a condition or disease caused by hypoadiponectin. For example, it can be used for treating or improving metabolic syndrome, life style cancer, insulin resistance syndrome, diabetes (including type I diabetes and type II diabetes), diabetic complications (including retinopathy, renal failure, neurosis, cataract, coronary artery disease, etc.), arteriosclerosis, coronary artery disease, renal dysfunction, myocardial infarction, hypertension, cerebrovascular disease, hyperlipidemia, hypercholesterolemia, obesity, bone density reduction, liver disease, etc. In addition, the adiponectin secretion promoter of the present invention is also useful for anti-aging.

The adiponectin secretion promoter of the present invention can be administered in the form of a pharmaceutical product. The medicine of the invention can take the island thistle as an effective component and is prepared according to a conventional method. Examples of the preparations for oral administration include solid or liquid preparations, and specifically include tablets (including sugar-coated tablets and film-coated tablets), pills, granules, powders, capsules (including soft capsules), syrups, emulsions, and suspensions. These preparations can be prepared by known methods, and contain carriers, diluents or adjuvants conventionally used in the field of pharmaceutical preparations. For example, lactose, starch, sucrose, magnesium stearate, and the like can be used as a carrier or excipient for tablets. As a preparation for parenteral administration, for example, injections, suppositories and the like can be used, and the injections include intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, intravenous drip injections, intra-articular injections and the like. Such an injection can be prepared by a known method, for example, by dissolving, suspending or emulsifying the above active ingredient in a sterile aqueous or oily liquid usually used for injections. Examples of the aqueous liquid for injection include physiological saline, isotonic solutions containing glucose or other auxiliary agents, and the like, and suitable cosolvents such as alcohols (e.g., ethanol, etc.), polyols (e.g., propylene glycol, polyethylene glycol, etc.), nonionic surfactants (e.g., polysorbate 80, HCO-50, etc.), and the like may be used in combination. As the oily liquid, for example, sesame oil, soybean oil, etc. may be used, and benzyl benzoate, benzyl alcohol, etc. may be used together as a cosolvent. Suppositories for rectal administration can be prepared by mixing the above-mentioned active ingredients with a usual suppository base.

The adiponectin secretion promoter of the present invention can be ingested in the form of a food or beverage. The food and drink includes health food, functional food, specific health food, food for patients, and nutritional supplementary food (supplement). The form of the food or drink is not particularly limited. Examples of the beverage include beverages such as tea beverages, refreshing beverages, carbonated beverages, nutritional beverages, fruit beverages, and lactic acid beverages; buckwheat flour, udon flour, Chinese flour, instant flour, etc.; confectionery such as sugar, candy, chewing gum, chocolate, snack, biscuit, jelly, jam, cream, baked confectionery, bread, and bread; fish cake, ham, sausage, etc. and processed food of livestock; processed milk, fermented milk, and other dairy products; salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, sauce, etc. and oil processed food; sauce, seasoning juice, etc.; steaming and boiling bagged food such as curry, stewed dish, rice with a cover, porridge, vegetable porridge and the like; ice food such as ice cream, water ice, and water ice. The nutritional supplement food (supplement) can be provided in the form of, for example, tablets, granules, powders, drinks, and the like.

Since the drug for improving insulin resistance containing the adiponectin secretion promoter of the present invention or the food or beverage for promoting adiponectin secretion containing the adiponectin secretion promoter of the present invention contains, as an active ingredient, artichoke which is used as a conventional food material, it can be safely used in humans or mammals other than humans (for example, rats, mice, rabbits, sheep, pigs, cows, cats, dogs, monkeys, etc.).

The administration amount or intake amount of the above-mentioned medicine, food or drink can be determined according to the age and weight of the patient or the person who takes the medicine, symptoms, administration time, dosage form, administration method, combination of the drugs, and the like. For example, when the adiponectin secretion promoter of the present invention is orally administered as a medicine, 0.1g or more, 0.2g or more, 0.3g or more, 0.4g or more, 0.5g or more, 0.6g or more, 0.7g or more, 0.8g or more, 0.9g or more, 1.0g or more per day can be administered to an adult per person in terms of a dried powder of Cynara scolymus, and 20g or less, 18g or less, 16g or less, 15g or less, 14g or less, 13g or less, 12g or less, 11g or less, and 10g or less can be administered. Administration may also be divided into multiple administrations per day (e.g., 3).

When the adiponectin secretion promoter of the present invention is ingested as a food or beverage, the adiponectin secretion promoter may be incorporated in such a manner that the daily intake of an adult per person is 0.1g or more, 0.2g or more, 0.3g or more, 0.4g or more, 0.5g or more, 0.6g or more, 0.7g or more, 0.8g or more, 0.9g or more, or 1.0g or more, or 20g or less, 18g or less, 16g or less, 15g or less, 14g or less, 13g or less, 12g or less, 11g or less, or 10g or less, based on the dried powder of artichoke. It can also be divided into multiple (e.g., 3) daily intakes.

Examples

The present invention will be described in detail below with reference to examples, but the present invention is not limited thereto.

Example 1: effect of Cynara scolymus on human lipid metabolism ]

< test method >

(1) Test subject

In Japanese males and females aged 20 to 80 years at the time of consent, 24 males and females with a critical level or marginal elevation (120 to 159mg/dL) in LDL cholesterol value or a suitable high level and marginal elevation (120 to 199mg/dL) in neutral fat value were used as subjects.

(2) Preparation and ingestion of Cynara scolymus L

The artichoke leaves are washed by water and then sterilized by hypochlorous acid. Then, the water is sufficiently controlled and pre-frozen. Next, the artichoke leaves were freeze-dried using a vacuum drying apparatus (Marui co., Ltd). Pulverizing the freeze-dried leaves with a pulverizer, and sieving to remove non-powder substances to obtain freeze-dried powder of the Cynara scolymus leaves. The subjects ingested 3g of isara scolymus powder per time, 3 times per day (9 g/day), for 12 weeks. Specifically, an islanding juice is prepared by adding water (100-150 mL) to 3g of islanding powder at a time, and is drunk.

(3) Measurement items

Body measurement: height (first time only), weight, body fat percentage

Routine biochemical examination: glucose, HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, and neutral fat

Adiponectin in blood

Free fatty acids

The BMI is calculated using the following formula. BMI ═ body weight (kg) ÷ [ body height (m)]²

Glucose, HbA1c, total cholesterol, HDL cholesterol, LDL cholesterol, and neutral fat were measured by LSI Mediate Corporation.

Adiponectin was measured using a human adiponectin ELISA kit (Otsuka Pharmaceutical co., Ltd.).

Free fatty acids were determined using NEFA C-Test Wako (Wako Pure Chemical Industries, Ltd.).

(4) Test schedule

Body measurement and blood collection (8mL) were performed before the start of ingestion of the israja juice, 4 weeks after ingestion, 8 weeks after ingestion, and 12 weeks after ingestion, and the measurement was performed for each item.

< results >

The measurement values at the respective time points were compared with each other with the measurement values before the start of the intake as references, and the results of the corresponding t-tests are shown in table 1 (mean ± standard deviation). Body weight, BMI, neutral fat, free fatty acids and fasting plasma glucose values were unchanged. Body fat rates increased significantly 8 weeks after the start of ingestion and 12 weeks after. Total cholesterol rose significantly after 12 weeks from the start of ingestion. HDL cholesterol increased significantly after 4 weeks, 8 weeks, and 12 weeks after the start of ingestion. LDL cholesterol increased significantly after 8 weeks and 12 weeks from the start of ingestion. HbA1c rose significantly 4 weeks and 12 weeks after the start of ingestion. Adiponectin rose significantly after 8 weeks and 12 weeks after the start of ingestion.

[ Table 1]

*: p < 0.05VS pre-uptake

The present invention is not limited to the above embodiments and examples, and various modifications can be made within the scope of the claims, and embodiments obtained by appropriately combining technical means disclosed in different embodiments are also included in the technical scope of the present invention.